QR678 Treatment

Suitability depends on the cause and stage of hair loss. The strongest published QR678 evidence is for androgenetic alopecia, including male pattern hair loss and female pattern hair loss. Patients with other causes of hair loss require diagnosis-specific assessment before QR678 is considered.

• Male Pattern Hair Loss: Men with clinically assessed androgenetic alopecia may be considered, especially when miniaturizing follicles remain and a non-surgical plan is appropriate.
• Female Pattern Hair Loss: Selected women with female pattern hair loss may be considered after assessment of other possible causes such as iron deficiency, thyroid disease, postpartum changes or hormonal disorders.
• Early to Moderate Thinning: Non-surgical treatments are generally more relevant where follicles remain in thinning areas rather than long-standing completely bald skin.
• Patients Comparing Non-Surgical Options: QR678 may be discussed alongside PRP, GFC, medication-based management or other therapies, depending on diagnosis and patient factors.

Important: Alopecia areata, telogen effluvium, post-chemotherapy alopecia and other conditions have been studied in smaller QR678 trials, but they should not be marketed as identical indications or treated without first addressing the underlying diagnosis.

Published studies have evaluated QR678 Neo using intradermal injections into the scalp, and some research has also compared intradermal administration with microneedling/derma-roller delivery. The method used at Dermatrix should match the current product instructions, clinician training and clinic protocol.

Before treatment, the clinician should confirm the diagnosis, treatment area, medical history and suitability. During the procedure, the product is delivered into selected scalp areas using the clinic’s verified protocol. Patients may experience temporary local discomfort, redness or sensitivity depending on the administration method.

QR678 Neo has multiple peer-reviewed publications, including a large open-label multi-centre study in 2,428 patients with androgenetic alopecia/female pattern hair loss, a randomized comparative study versus PRP, prospective studies in other hair-loss conditions and more recent work evaluating QR678 Neo around hair transplantation.

This evidence is encouraging, but it should be interpreted carefully. Several studies are open-label, single-centre or relatively small, and many were conducted by investigators closely involved with development of the QR678 platform. Dermatrix should therefore avoid presenting any study result as a guaranteed outcome for every patient.

Many published QR678 Neo protocols used eight treatment sessions, often spaced about three to four weeks apart. Dermatrix’s live page currently states 8–10 sessions every 2–3 weeks. The website should display only the schedule that matches Dermatrix’s current medical protocol and the exact QR678 product instructions.

Session number may change according to diagnosis, severity, response and whether QR678 is being used alone or as part of a broader hair-loss plan. Avoid promising that every patient needs the same number of sessions

In published studies, QR678 Neo has been associated with reductions in hair fall and improvements in terminal-hair count, shaft diameter or hair-density measures in selected patients. Hair change is gradual, so progress is generally assessed over several months rather than immediately after treatment.

Individual response depends on the diagnosis, stage of follicle miniaturization, age, baseline density, ongoing progression, adherence to the treatment plan and use of other therapies. Avoid guarantees such as “revives all dormant follicles,” “90% success,” “permanent results” or a fixed visible-result timeline unless a specific claim can be substantiated and is appropriate for the exact product used.

Published studies have generally reported good tolerability, but no medical procedure should be described as having “zero side effects” for every patient. Depending on the administration method, temporary injection-site pain, redness, swelling, sensitivity or pinpoint bleeding can occur. The treating clinician should explain contraindications, expected local effects and aftercare before treatment.

• Follow Dermatrix’s exact instructions about washing the scalp and applying hair products after treatment.
• Avoid scratching or aggressively massaging treated areas immediately after the procedure.
• Report significant or persistent pain, swelling, rash, infection signs or any unexpected reaction.
• Continue any prescribed medical hair-loss treatment only as directed by the clinician.
• Attend scheduled review visits so progress can be assessed objectively.